GASTROINTESTINAL CANCER

NCCTG胃肠道（GI）癌症项目汇集了来自所有肿瘤学科的专家，目标如下：1。尽可能提高治愈率或延长生存期/改善患者生活质量。a）发起/领导GI Intergroup/NCCTG III期临床试验。B）参与由其他肿瘤学组领导的GI组间试验。c）根据马约诊所I期项目或其他地方与NCCTG新疗法委员会合作开发的最有前景的GI癌症治疗策略，快速启动/完成初步研究和II期试验。这一策略体现在对八个主要胃肠道部位进行的靶向研究中。d）多种模式（手术、放射和内科肿瘤学）的整合以及适当模式委员会参与试验设计和实施。2.设计可在患者家附近进行的治疗，并在适当时转诊至专业中心。a）在研究和社区基础之间建立研究驱动的伙伴关系。B）在NCCTG会议期间和会议前后举办教育专题讨论会。3)通过研究预后决定因素、影响疾病进展的因素和个体对化疗的反应（即转化研究），进一步了解肿瘤生物学和宿主反应。a）与具有相关科学专业知识的马约诊所研究人员互动。B）与其他地方的实验室研究者合作。4.在已完成的研究中使用广泛的NCCTG数据库，以回答临床实践中、前瞻性试验分析或文献中出现的问题。5.监测和改善患者的生活质量（QOL）和评估QOL的工具。6.通过设计新的试验范式和系统来优化数据收集，以应对我们研究中出现的问题，从而推动临床试验研究领域的发展。7.吸引多学科肿瘤学团队的不同成员参与致力于扩展癌症护理视野的合作。此应用程序将集中在过去，现在，并根据我们在最后一个赠款期间的成就NCCTG GI计划的预测未来。我们将根据上述哲学原则，描述具体的方案方法，定义NCCTG GI计划。我们将专注于我们在前一个资助期（现在）的成就，并规划主题和概述我们希望在下一个资助期（未来）定义我们的计划的新举措。

The NCCTG Gastrointestinal (GI) Cancer Program brings together specialists from all oncology disciplines with the following goals: 1. To improve cure rates when possible or extend survival/improve patient quality of life. a) Initiation/leadership of GI Intergroup/NCCTG phase III clinical trials. b) Participation in GI Intergroup trials led by other oncology groups. c) Rapid initiation/completion of Pilot Studies and Phase II trials, based on the most promising GI cancer treatment strategies developed in the Mayo Clinic Phase I program or elsewhere in collaboration with the NCCTG Novel Therapeutics Committee. This strategy manifests itself in the performance of targeted research studies across the eight primary GI tract sites. d) Integration of multiple modalities (surgery, radiation, and medical oncology) and participation of the appropriate modality committees in trial design and conduct. 2. To devise therapies that an be administered in proximity to the patient's home, with referral to specialized centers when approprite. a) By forging a research-driven partnership between the research and community bases. b) By conducting education symposia based in and around NCCTG meetings. 3) To further the understanding of tumor biology and host response through the investigation of prognostic determinants, factors influencing disease progression, and individual responses to chemotherapy (i.e. translational research). a) Interaction with Mayo Clinic researchers with expertise in correlative science. b) Collaboration with laboratory-based investigators elsewhere. 4. To utilize the extensive NCCTG database in completed studies to answer questions arising in clinical practice, from analyses of prospective trials, or from the literature. 5. To monitor and improve patient quality of life (QOL) and the tools to assess QOL. 6. To advance the field of clinical trials research by design of new trial paradigms and systems for optimal data collection in response to issues arising from our studies. 7. To entice involvement from diverse members of the multi-disciplinary oncology team in collaborations dedicated to extending the horizons of cancer care. This application will focus on the past, present, and projected future of the NCCTG GI Program based upon our accomplishments during the last grant period. We will delineate specific programmatic approaches that define the NCCTG GI Program based on the philosophical principles noted above. We will concentrate on our accomplishments in the prior grant period (present), and project the themes and outline the new initiatives that we hope will define our program in the next grant period (future).